Cargando…

Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)

BACKGROUND: There is no standardized approach to the management of JDM-associated calcinosis and its phenotypes. Current knowledge of treatment outcomes is confined to small series and case reports. We describe physician perspectives toward diagnostic approach, classification and treatment directly...

Descripción completa

Detalles Bibliográficos
Autores principales: Orandi, A. B., Baszis, K. W., Dharnidharka, V. R., Huber, A. M., Hoeltzel, M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609060/
https://www.ncbi.nlm.nih.gov/pubmed/28934971
http://dx.doi.org/10.1186/s12969-017-0199-4
_version_ 1783265543609909248
author Orandi, A. B.
Baszis, K. W.
Dharnidharka, V. R.
Huber, A. M.
Hoeltzel, M. F.
author_facet Orandi, A. B.
Baszis, K. W.
Dharnidharka, V. R.
Huber, A. M.
Hoeltzel, M. F.
author_sort Orandi, A. B.
collection PubMed
description BACKGROUND: There is no standardized approach to the management of JDM-associated calcinosis and its phenotypes. Current knowledge of treatment outcomes is confined to small series and case reports. We describe physician perspectives toward diagnostic approach, classification and treatment directly targeting calcinosis, independent of overall JDM therapy. METHODS: An electronic survey of 22 questions was organized into sections regarding individual practices of assessment, classification and treatment of calcinosis, including perceived successes of therapies. Invitations to complete the survey voluntarily and anonymously were sent to CARRA physician members and the Pediatric Rheumatology Bulletin Board, an electronic list-serv. Results were analyzed by descriptive statistics and chi-square analyses. RESULTS: Of 139 survey responses, 118 were included in analysis. Of these, 70% were based in the USA and 88 (75%) were CARRA members. Only 17% of responders have seen more than 20 cases of calcinosis, and only 28% perform screening imaging studies on new JDM diagnoses. Increasing systemic immunosuppression is first-line therapy for 67% of respondents. Targeted therapy against calcinosis is most often instituted for symptomatic patients. IVIG and bisphosphonates are most frequently used and considered most successful, but many other agents are used. Experienced physicians are more likely to use bisphosphonates, calcium channel blockers and topical sodium thiosulfate (p< 0.002 or lower). CONCLUSIONS: Coexisting JDM disease activity influences whether calcinosis is considered active disease or targeted directly. Experience treating JDM-related calcinosis is low, as are rates of formal screening for calcinosis. Experienced physicians are more likely to use non-immunosuppressive treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1186/s12969-017-0199-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5609060
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56090602017-09-25 Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA) Orandi, A. B. Baszis, K. W. Dharnidharka, V. R. Huber, A. M. Hoeltzel, M. F. Pediatr Rheumatol Online J Research Article BACKGROUND: There is no standardized approach to the management of JDM-associated calcinosis and its phenotypes. Current knowledge of treatment outcomes is confined to small series and case reports. We describe physician perspectives toward diagnostic approach, classification and treatment directly targeting calcinosis, independent of overall JDM therapy. METHODS: An electronic survey of 22 questions was organized into sections regarding individual practices of assessment, classification and treatment of calcinosis, including perceived successes of therapies. Invitations to complete the survey voluntarily and anonymously were sent to CARRA physician members and the Pediatric Rheumatology Bulletin Board, an electronic list-serv. Results were analyzed by descriptive statistics and chi-square analyses. RESULTS: Of 139 survey responses, 118 were included in analysis. Of these, 70% were based in the USA and 88 (75%) were CARRA members. Only 17% of responders have seen more than 20 cases of calcinosis, and only 28% perform screening imaging studies on new JDM diagnoses. Increasing systemic immunosuppression is first-line therapy for 67% of respondents. Targeted therapy against calcinosis is most often instituted for symptomatic patients. IVIG and bisphosphonates are most frequently used and considered most successful, but many other agents are used. Experienced physicians are more likely to use bisphosphonates, calcium channel blockers and topical sodium thiosulfate (p< 0.002 or lower). CONCLUSIONS: Coexisting JDM disease activity influences whether calcinosis is considered active disease or targeted directly. Experience treating JDM-related calcinosis is low, as are rates of formal screening for calcinosis. Experienced physicians are more likely to use non-immunosuppressive treatments. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1186/s12969-017-0199-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-21 /pmc/articles/PMC5609060/ /pubmed/28934971 http://dx.doi.org/10.1186/s12969-017-0199-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Orandi, A. B.
Baszis, K. W.
Dharnidharka, V. R.
Huber, A. M.
Hoeltzel, M. F.
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)
title Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)
title_full Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)
title_fullStr Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)
title_full_unstemmed Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)
title_short Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA)
title_sort assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (carra)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609060/
https://www.ncbi.nlm.nih.gov/pubmed/28934971
http://dx.doi.org/10.1186/s12969-017-0199-4
work_keys_str_mv AT orandiab assessmentclassificationandtreatmentofcalcinosisasacomplicationofjuveniledermatomyositisasurveyofpediatricrheumatologistsbythechildhoodarthritisandrheumatologyresearchalliancecarra
AT basziskw assessmentclassificationandtreatmentofcalcinosisasacomplicationofjuveniledermatomyositisasurveyofpediatricrheumatologistsbythechildhoodarthritisandrheumatologyresearchalliancecarra
AT dharnidharkavr assessmentclassificationandtreatmentofcalcinosisasacomplicationofjuveniledermatomyositisasurveyofpediatricrheumatologistsbythechildhoodarthritisandrheumatologyresearchalliancecarra
AT huberam assessmentclassificationandtreatmentofcalcinosisasacomplicationofjuveniledermatomyositisasurveyofpediatricrheumatologistsbythechildhoodarthritisandrheumatologyresearchalliancecarra
AT hoeltzelmf assessmentclassificationandtreatmentofcalcinosisasacomplicationofjuveniledermatomyositisasurveyofpediatricrheumatologistsbythechildhoodarthritisandrheumatologyresearchalliancecarra
AT assessmentclassificationandtreatmentofcalcinosisasacomplicationofjuveniledermatomyositisasurveyofpediatricrheumatologistsbythechildhoodarthritisandrheumatologyresearchalliancecarra